https://www.selleckchem.com/products/R406.html
Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) 65%] in a 'real world' national cohort of AF patients. The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 card
Like
Comment
Share
